August 15, 2017 11:02 AM EDT
News Briefing

Biosims mak­ing slow progress bat­tling block­busters for mar­ket share; Fi­bro­Gen rais­ing $300M

Shehla Shakoor

Managing Director

⇨ Bloomberg has a re­port out to­day that il­lus­trates just how slow­ly biosim­i­lars are able to pen­e­trate some of the world’s biggest fran­chis­es. Some say …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Im­munol­o­gy biotech In­ma­gene to join Nas­daq through re­verse merg­er with what's left of Ike­na

A service from the Financial Times